XERIS BIOPHARMA HOLDINGS, INC. Jefferies Global Healthcare Conference in London - XERIS BIOPHARMA HOLDINGS INC
Explicit Guidance:
- Full-year 2024 revenue guidance raised to $395–$405 million (midpoint implies 37% growth), driven by three core products.
- 2030 revenue outlook raised from $750 million to > $1 billion, attributed to growth trajectories of Recorlev, G-Voke, and Caveas.
- Full-year 2025 outlook: Anticipates "significant growth year" across all three core products; specifically projects 9–10% revenue growth for G-Voke and growth for Caveas (previously flat/steady).
- 2028 Top-line data disclosure target for Phase 3 program (8121) for hypothyroidism.
- 2030 Approval target for 8121 (hypothyroidism).
- 8121 Peak Sales Range: $1–$3 billion.
Business-Segment Outlook:
- Recorlev (Cushing's): Sales force doubled in January; Q3 sales exceeded $71 million, placing the product on a trajectory to reach $1 billion in revenue in 3–4 years (accelerated from previous 2035 target). Growth driven by guideline updates (ADA/ESAD) expanding testing to primary care physicians for patients with resistant diabetes/hypertension/obesity.
- G-Voke (Hypoglycemia): Market returning to growth; captures "more than fair share." Estimated market opportunity of 15 million patients with <1 million currently utilizing ready-to-use glucagon. Targeting high single-digit to low double-digit growth indefinitely.
- Caveas (PPP): Re-entering growth phase following early Q4 investments in field personnel. Addresses estimated 4,000–5,000 patients.
- 8121 (Hypothyroidism): Phase 3 program initiation expected by end of 2024. Focused on 3–5 million patients unable to meet goals on oral levothyroxine; aims for 10% penetration (300k–500k patients) to achieve peak sales.
Market and Competitive Outlook:
- Recorlev: Demand accelerating as clinicians increasingly test for hypercortisolism; guidelines now recommend testing if cortisol >1.8x upper limit of normal. Prescriber base expanding from endocrinologists to primary care physicians (PCPs).
- G-Voke: Focus on changing physician behavior and practice protocols to ensure routine prescribing of glucagon; penetration remains significantly below guidelines.
- Payer Dynamics: Recorlev faces no immediate widespread access restrictions; category requires "prior authorization" and "medical necessity" but remains limited in volume (40k–50k patients), mitigating broad payer pushback.
- 8121 Access Strategy: Anticipated access based on "failure on oral" criteria; leveraging existing patient data to satisfy prior authorization requirements for patients who cannot achieve biochemical control on standard of care.
Macro / Industry Outlook:
- Hypothyroidism Innovation: No significant product innovation in 40+ years; high KOL enthusiasm for once-weekly subcutaneous therapy.
- Real-World Evidence (RWE): Initiating RWE generation to characterize unmet need (25% of analyzed patients out of range twice in one year vs. annual testing).
- FDA Alignment: Strong alignment with agency on study design for 8121 (non-inferiority trial) to maximize approval probability.
Strategic Initiatives:
- Commercial Expansion: Recorlev sales force doubled in January (third expansion since 2022 launch).
- Product Development:
- Initiate Phase 3 (Cornerstone) for 8121 by end of 2024.
- Initiate "Touchstone" special population study (poorly controlled patients) in 2025.
- Initiate "Capstone" pediatric study.
- Conduct real-world evidence generation pre-launch.
- M&A / BD: Business Development (BD) identified as "next frontier" to leverage cash flow and balance sheet; targeting assets contributing revenue/growth in next 3–6 years before 8121 materializes; focus on rare/endocrinology assets.
- Patient Support: Enhanced field personnel for Caveas to identify and support ultra-rare patient cohorts.
Risks and Headwinds to Outlook:
- Patient Drop-out: Risk of discontinuation in first 3–4 months due to cortisol withdrawal and complex medication adjustments (hypertension/diabetes); persistence expected to stabilize after this period.
- Payer Restrictions: Potential future access challenges, though currently deemed unlikely for Recorlev due to small market size and medical necessity requirements.
- Clinical Execution: Phase 3 approval relies on non-inferiority; while superiority is possible, it is not counted on for peak sales assumptions.
- BD Discipline: M&A activity will be selective; management emphasizes disciplined execution over necessity.
Management Tone on the Future:
- High Confidence: Describes Recorlev as being on a "new growth trend" with "tremendous growth" and "aggressive" acceleration.
- Aggressive but Disciplined: Raised 2030 guidance from $750M to >$1B based on "better than expected" Q3 performance; BD strategy is "aggressive" but constrained by a need to "meet expectations."
- Optimistic: Strong enthusiasm from KOLs and physicians regarding 8121; pricing assumptions described as "conservative and achievable."
Miscellaneous:
- Financial Health: Company profitable for over a year with 88% gross margins (growing each quarter); cash generation priority shifting toward BD.
- Pricing: Specific pricing for 8121 not yet guided due to 2030 approval timeline; assumptions based on 10% of 3–5 million addressable market.
- Company
- XERIS BIOPHARMA HOLDINGS INC
- Keywords
- XERIS BIOPHARMA HOLDINGS INC